Compare Nasdaq Inc (NDAQ) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Nasdaq Inc trades at $93.65 (market cap $51.63B), while Vertex Pharmaceuticals Incorporated trades at $510.08 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.5× Nasdaq Inc's market cap, and Nasdaq Inc pays a 1.26% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nasdaq Inc for 126 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| NDAQ | VRTX | |
|---|---|---|
Market Cap | $51.63B | $127.55B |
Volume | 2,668,175 | 1,487,944 |
Sector | Financials | Health |
52-Week High | $100.98 | $557.96 |
52-Week Low | $76.85 | $407.37 |
Typical Hold Time | 126 Days | 120 Days |
Enterprise Value | $58.09B | $121.68B |
Dividend Yield | 1.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nasdaq Inc. (NDAQ) trades at $92.37, up 0.48% today, with a bullish technical signal from moving averages and strong fundamental performance including a 21.64% net income margin and consistent earnings beats. Recent news highlights growth in its Financial Technology business, such as HSBC adopting Nasdaq Calypso for derivatives clearing (GlobeNewsWire, 2026-09-28).
The outlook is positive with a consensus price target of $110.43, implying 19.6% upside, supported by robust profitability and AI-driven initiatives. Risks include high valuation multiples and market volatility, but analyst sentiment is strongly bullish with 61% buy ratings.
Vertex Pharmaceuticals (VRTX) trades at $503.25, down 0.47% on the day, with a bearish technical signal despite strong fundamentals. The company maintains dominant cystic fibrosis market position with 86% gross margins and 35% net income margin. Recent positive Phase 2b data for inaxaplin in kidney disease shows pipeline expansion potential. Revenue grew to $12.0B in 2025 with $3.95B net income, recovering from 2024's loss.
Analyst consensus remains strongly bullish with 84% buy ratings and $573.50 price target, representing 14% upside. Key risks include pipeline execution and competitive pressures. The stock offers growth potential through gene therapy expansion but faces volatility from clinical trial outcomes and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
